Drug Trial Radar · NCT06486142
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Sep 21, 2022
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Region SkaneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Swedish Lung Cancer Study Group
- First posted
- Jul 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.
Conditions
- Non-Small Cell Lung Cancer
Interventions
Afatinib/DacomitinibDrug
Second-generation EGFR-inhibitors
OsimertinibDrug
Third-generation EGFR-inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Maximum 6 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Skåne university hospital
Lund, Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.